Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_2

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

NCT04560894
unknownphase_1

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT05552807
unknownphase_1

Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

NCT04229537
unknownphase_1

Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma

NCT03821363

Clinical Trials (4)

Showing 4 of 4 trials
NCT04560894Phase 2

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Unknown
NCT05552807Phase 1

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Unknown
NCT04229537Phase 1

Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Unknown
NCT03821363Phase 1

Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4